Navigation Links
PreHistin ® Allergy Defense Formula Wins 2011 Best New Product Award at ECRM Allergy Show
Date:3/10/2011

IRVINE, Calif., March 10, 2011 /PRNewswire/ -- Cobalis Corp.'s (Pink Sheets: CLSC) http://www.prehistin.com/  [PreHistin® Allergy Defense Formula], the first ever pre-histamine, has taken the coveted 2011 Best New Product Award at the ECRM Cough, Cold and Allergy show held in Orlando, FL, February 28-March 3. PreHistin® regulates overproduction of the key allergen antibody IgE to restore a normal response to both seasonal and year-round allergens, which according to leading US allergist and clinical researcher Dr. Paul H. Ratner, MD is "no allergic response at all!"

"We are very proud that PreHistin® was selected by the country's leading retail and pharmacy buyers as 'Best New Product of the Year' out of a field of thousands of products. In introducing PreHistin® as the world's first PRE-histamine, we have literally created an entirely new category in allergy care, as well as offering the more than 60 million Americans who suffer from seasonal and year-round allergies the first major new option available in years – the opportunity to regulate allergen antibody IgE levels to restore a normal, non-reactive response to allergens, as opposed to treating symptoms after an allergic reaction has started. We thank the retailers and distributors who attended this show for awarding us this great honor and recognition," said Marty Marion, CEO of Cobalis Corp.

PreHistin® is now on shelves at one of the nation's two largest drugstore chains, and is expected to be on pharmacy and grocery shelves across the country very quickly. Indoor and outdoor allergy sufferers, who need relief seasonally or year-round, can feel the benefits of PreHistin® in as little as a few weeks of regular use. The all-natural formula of PreHistin® is a lozenge dissolved under the tongue and then swallowed twice a day during allergy season, or year-round for those who suffer from indoor allergens like dust, mold and pet dander.

"I recommend that all of my patients who suffer from allergies use PreHistin®," said allergist Dr. Paul Ratner. "Not only is the product safe but it is extremely effective, completely non-drowsy, and has no side effects."

Readers who are interested in more information should visit www.prehistin.com. To arrange a media interview with Dr. Paul Ratner please contact Nancy Trent or Pam Wadler at 212-966-0024 or send an email to pam@trentandcompany.com.

ABOUT PREHISTIN® ALLERGY DEFENSE FORMULA

PreHistin® Allergy Defense Formula is a unique, patented cobalamin complex product that helps rebalance the immune system to lower allergen antibody IgE levels, and regulate the release of symptom-linked histamine which is linked to the onset of symptoms such as sneezing, itchy watery eyes, runny nose and nasal congestion. PreHistin® is a cherry-flavored lozenge that is dissolved under the tongue and then swallowed twice a day, usually starting before the allergy season, or taken daily for those suffering from year-round allergies. PreHistin® has no known side effects, is 100% non-drowsy, and has no contraindications with any other medications. In clinical trials on thousands of allergy sufferers, PreHistin® was shown to be safe and effective in reducing nasal symptoms.

ABOUT COBALIS CORP.—PREHISTIN®

Cobalis Corp. is a specialty pharmaceutical, nutraceutical and preventive healthcare product development and marketing company. Its flagship product, PreHistin® Allergy Defense Formula, "The World's First Pre-Histamine", is designed to mitigate overproduction of IgE levels and restore a normal response to seasonal and year-round indoor and outdoor allergens. PreHistin® is now available without prescription for both long-term and daily use.

For PreHistin® product information please visit www.PreHistin.com or call toll free

1-877-4POLLEN (1-877-476-5536). For additional company information please visit the corporate website at www.Cobalis.com. CONTACTCobalis Corp.949-260-0123Chas Radovich, PresidentMartin Marion, CEOinfo@cobalis.com
'/>"/>

SOURCE Cobalis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cobalis Corp. Receives $415,000 First Purchase Order from Major Retail Pharmacy for PreHistin® Allergy Defense Formula
2. Sams Club® Offers Free Allergy Health Screenings
3. Good Clostridia in the Gut Protect from Allergy and Autoimmunity
4. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
5. Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology
6. Cetero Research Leads Industry in Human Allergy Models
7. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
8. National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production
9. Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
10. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
11. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):